| Identification of cancer biomarkers of prognostic value using specific gene regulatory networks (GRN): a novel role of RAD51AP1 for ovarian and lung cancers D Chudasama, V Bo, M Hall, V Anikin, J Jeyaneethi, J Gregory, G Pados, ... Carcinogenesis 39 (3), 407-417, 2018 | 51 | 2018 |
| Differential expression of mTOR components in endometriosis and ovarian cancer: Effects of rapalogues and dual kinase inhibitors on mTORC1 and mTORC2 stoichiometry KR Rogers‑Broadway, J Kumar, C Sisu, G Wander, E Mazey, ... International journal of molecular medicine 43 (1), 47-56, 2019 | 39 | 2019 |
| A pancancer overview of FBN1, asprosin and its cognate receptor OR4M1 with detailed expression profiling in ovarian cancer R Kerslake, M Hall, P Vagnarelli, J Jeyaneethi, HS Randeva, G Pados, ... Oncology letters 22 (3), 1-14, 2021 | 25 | 2021 |
| Surfactant protein D as a potential biomarker and therapeutic target in ovarian cancer J Kumar, V Murugaiah, G Sotiriadis, A Kaur, J Jeyaneethi, I Sturniolo, ... Frontiers in Oncology 9, 542, 2019 | 21 | 2019 |
| Identification of potential bisphenol A (BPA) exposure biomarkers in ovarian cancer A Zahra, Q Dong, M Hall, J Jeyaneethi, E Silva, E Karteris, C Sisu Journal of Clinical Medicine 10 (9), 1979, 2021 | 17 | 2021 |
| H2A histone family member X (H2AX) is upregulated in ovarian cancer and demonstrates utility as a prognostic biomarker in terms of overall survival S Saravi, E Katsuta, J Jeyaneethi, HA Amin, M Kaspar, K Takabe, ... Journal of clinical medicine 9 (9), 2844, 2020 | 14 | 2020 |
| Differential regulation of genes by the glucogenic hormone asprosin in ovarian cancer R Kerslake, C Sisu, S Panfilov, M Hall, N Khan, J Jeyaneethi, H Randeva, ... Journal of Clinical Medicine 11 (19), 5942, 2022 | 9 | 2022 |
| Involvement of the glutamine RF‑amide peptide and its cognate receptor GPR103 in prostate cancer MA Kawan, I Kyrou, M Ramanjaneya, K Williams, J Jeyaneethi, ... Oncology Reports 41 (2), 1140-1150, 2019 | 8 | 2019 |
| Identification of cancer-associated circulating cells in anal cancer patients TJ Carter, J Jeyaneethi, J Kumar, E Karteris, R Glynne-Jones, M Hall Cancers 12 (8), 2229, 2020 | 7 | 2020 |
| Differential Expression of RAD51AP1 in Ovarian Cancer: Effects of siRNA In Vitro A Filipe, P Katopodis, D Chudasama, R Kerslake, J Jeyaneethi, V Anikin, ... Journal of Personalized Medicine 12 (2), 201, 2022 | 1 | 2022 |
Emmanouil Karteris PhD, FRSBBrunel UniversityBestätigte E-Mail-Adresse bei brunel.ac.uk
